Evaxion A/S announced new three-year clinical outcome data from its phase 2 trial evaluating the personalized cancer vaccine EVX-01 in patients with advanced melanoma. The findings show that all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results